The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways

Biomaterials

Volumn 33, Issue 33, 2012, Pages 8418-8429

  Salbach, Juliane ^a   Kliemt, Stefanie ^b   Rauner, Martina ^a   Rachner, Tilman D ^a   Goettsch, Claudia ^a   Kalkhof, Stefan ^b   von Bergen, Martin ^b   Möller, Stephanie ^c   Schnabelrauch, Matthias ^c,d   Hintze, Vera ^e   Scharnweber, Dieter ^e,f   Hofbauer, Lorenz C ^a,f  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HELMHOLTZ CENTRE FOR ENVIRONMENTAL RESEARCH UFZ   (Germany)

^c Biomaterials Department   (Germany)

^d Jena Center for Soft Matter   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Chondroitin sulfate; Extracellular matrix (ECM); Hyaluronan; Osteoclast; Quantitative proteomics; Sulfated glycosaminoglycans

Indexed keywords

CHONDROITIN SULFATES; EXTRACELLULAR MATRICES; HYALURONAN; OSTEOCLAST; QUANTITATIVE PROTEOMICS; SULFATED GLYCOSAMINOGLYCANS;

BIOLOGICAL MATERIALS; GLUCOSE; MOLECULAR BIOLOGY; PROTEINS;

BONE;

CATHEPSIN K; GLYCOSAMINOGLYCAN; OSCAR PROTEIN; PROTEIN; SWAP 70 PROTEIN; TRAP PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL STRUCTURE; CELL VIABILITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; SULFATION;

ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; IMMUNOBLOTTING; MICE; OSTEOCLASTS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84866144294     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.028     Document Type: Article

References (47)

1. Douglas T., Hempel U., Mietrach C., Viola M., Vigetti D., Heinemann S., et al. Influence of collagen-fibril-based coatings containing decorin and biglycan on osteoblast behavior. J Biomed Mater Res A 2008, 84:805-816.
2. Mathieu L.M., Mueller T.L., Bourban P.-E.E., Pioletti D.P., Muller R., Manson J.A., et al. Architecture and properties of anisotropic polymer composite scaffolds for bone tissue engineering. Biomaterials 2006, 27:905-916.
3. Fini M., Giavaresi G., Torricelli P., Borsari V., Giardino R., Nicolini A., et al. Osteoporosis and biomaterial osteointegration. Biomed Pharmacother 2004, 58:487-493.
4. Scharnweber D., Beutner R., Roessler S., Michael J., Schwenzer B. Using electrochemical approaches for bio surface engineering of titanium based implants. Recent developements advanced medical dental materials using electrochemical methodologies 2009, Research Signpost, p. 101-62.
5. Bierbaum S., Douglas T., Hanke T., Scharnweber D., Tippelt S., Monsees T.K., et al. Collageneous matrix coatings on titanium implants modified with decorin and chondroitin sulfate: characterization and influence on osteoblastic cells. J Biomed Mater Res A 2006, 77:551-562.
6. Robey P.G., Boskey A.L. The composition of bone. Primer on the metabolic bone diseases and disorders of mineral metabolism 2009, 32-38. John Wiley & Sons, Inc, Hoboken, NJ, USA. C.J. Rosen (Ed.).
7. Prince C.W., Navia J.M. Glycosaminoglycan alterations in rat bone due to growth and fluorosis. J Nutr 1983, 113:1576-1582.
8. Salbach J., Rachner T.D., Rauner M., Hempel U., Anderegg U., Franz S., et al. Regenerative potential of glycosaminoglycans for skin and bone. J Mol Med 2012, 90:625-635.
9. Hofbauer L.C., Neubauer A., Heufelder A.E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001, 92:460-470.
10. Henriksen K., Bollerslev J., Everts V., Karsdal M.A. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev 2011, 32:31-63.
11. Ariyoshi W., Takahashi T., Kanno T., Ichimiya H., Shinmyouzu K., Takano H., et al. Heparin inhibits osteoclastic differentiation and function. J Cell Biol 2008, 103:1707-1717.
12. Shinmyouzu K., Takahashi T., Ariyoshi W., Ichimiya H., Kanzaki S., Nishihara T. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand. Biochem Biophys Res Commun 2007, 354:447-452.
13. Kunze R., Rösler M., Möller S., Schnabelrauch M., Riemer T., Hempel U., et al. Sulfated hyaluronan derivatives reduce the proliferation rate of primary rat calvarial osteoblasts. Glycoconj J 2010, 27:151-158.
14. Hintze V., Moeller S., Schnabelrauch M., Bierbaum S., Viola M., Worch H., et al. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009, 10:3290-3297.
15. van der Smissen A., Hintze V., Scharnweber D., Moeller S., Schnabelrauch M., Majok A., et al. Growth promoting substrates for human dermal fibroblasts provided by artificial extracellular matrices composed of collagen I and sulfated glycosaminoglycans. Biomaterials 2011, 32:8938-8946.
16. Hempel U., Hintze V., Möller S., Schnabelrauch M., Scharnweber D., Dieter P. Artificial extracellular matrices composed of collagen I and sulfated hyaluronan with adsorbed transforming growth factor β1 promote collagen synthesis of human mesenchymal stromal cells. Acta Biomater 2012, 8:659-666.
17. Bothner H., Waaler T., Wik O. Limiting viscosity number and weight average molecular weight of hyaluronate samples produced by heat degradation. Int J Biol Macromol 1988, 10:287-291.
18. Hintze V, Miron A, Möller S, Schnabelrauch M, Heinemann S, Worch H, et al. Artificial extracellular matrices of collagen and sulphated hyaluronan enhance the differentiation of human mesenchymal stem cells in the presence of dexamethasone. J Tissue Eng Regen Med 2012;(in press).
19. Lowry O., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
20. Junqueira L.C., Bignolas G., Mourão P.A., Bonetti S.S. Quantitation of collagen - proteoglycan interaction in tissue sections. Connect Tissue Res 1980, 7:91-96.
21. Farndale R.W., Buttle D.J., Barrett A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986, 883:173-177.
22. Balazs E.A., Berntsen K.O., Karossa J., Swann D.A. An automated method for the determination of hexosamines. Anal Biochem 1965, 12:559-564.
23. Lutter A.-H., Hempel U., Wolf-Brandstetter C., Garbe A.I., Goettsch C., Hofbauer L.C., et al. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. J Cell Biochem 2010, 109:1025-1032.
24. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012, 9:671-675.
25. Soares-Schanoski A., Gómez-Piña V., del Fresno C., Rodríguez-Rojas A., García F., Glaría A., et al. 6-Methylprednisolone down-regulates IRAK-M in human and murine osteoclasts and boosts bone-resorbing activity: a putative mechanism for corticoid-induced osteoporosis. J Leukoc Biol 2007, 82:700-709.
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
27. Vives V., Laurin M., Cres G., Larrousse P., Morichaud Z., Noel D., et al. The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. J Bone Miner Res 2011, 26:1099-1110.
28. Smith P., Krohn R., Hermanson G., Mallia A., Gartner F., Provenzano M., et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985, 150:76-85.
29. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372.
30. Hilpelä P., Oberbanscheidt P., Hahne P., Hund M., Kalhammer G., Small J.V., et al. SWAP-70 identifies a transitional subset of actin filaments in motile cells. Mol Biol Cell 2003, 14:3242-3253.
31. Takayanagi H. The role of NFAT in osteoclast formation. Ann NY Acad Sci 2007, 1116:227-237.
32. Haupt L.M., Murali S., Mun F.K., Teplyuk N., Mei L.F., Stein G.S., et al. The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. J Cell Physiol 2009, 220:780-791.
33. Hoshiba T., Kawazoe N., Tateishi T., Chen G. Development of stepwise osteogenesis-mimicking matrices for the regulation of mesenchymal stem cell functions. J Biol Chem 2009, 284:31164-31173.
34. Mark M.P., Baker J.R., Kimata K., Ruch J.V. Regulated changes in chondroitin sulfation during embryogenesis: an immunohistochemical approach. Int J Dev Biol 1990, 34:191-204.
35. Mucci A. 1H and 13C nuclear magnetic resonance identification and characterization of components of chondroitin sulfates of various origin. Carbohyd Polym 2000, 41:37-45.
36. Brown S.H., Pummill P.E. Recombinant production of hyaluronic acid. Curr Pharm Biotechnol 2008, 9:239-241.
37. Jiang D., Liang J., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011, 91:221-264.
38. Ruffell B., Johnson P. Chondroitin sulfate addition to CD44H negatively regulates hyaluronan binding. Biochem Biophys Res Commun 2005, 334:306-312.
39. Ruffell B., Poon G.F., Lee S.S., Brown K.L., Tjew S.L., Cooper J., et al. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages. J Biol Chem 2011, 286:19179-19190.
40. Barrow A.D., Raynal N., Andersen T.L., Slatter D.A., Bihan D., Pugh N., et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest 2011, 121:3505-3516.
41. Stamov D., Grimmer M., Salchert K., Pompe T., Werner C. Heparin intercalation into reconstituted collagen I fibrils: impact on growth kinetics and morphology. Biomaterials 2008, 29:1-14.
42. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007, 41:165-174.
43. Jurdic P., Saltel F., Chabadel A., Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol 2006, 85:195-202.
44. Saltel F., Chabadel A., Bonnelye E., Jurdic P. Actin cytoskeletal organisation in osteoclasts: a model to decipher transmigration and matrix degradation. Eur J Cell Biol 2008, 87:459-468.
45. Duong L.T., Lakkakorpi P., Nakamura I., Rodan G.A. Integrins and signaling in osteoclast function. Matrix Biol 2000, 19:97-105.
46. Garbe AI, Roscher A, Schüler C, Lutter A-H, Glösmann M, Bernhardt R, et al. Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. J Bone Miner Res 2012;(in press).
47. Becher J., Möller S., Weiss D., Schiller J., Schnabelrauch M. Synthesis of new regioselectively sulfated hyaluronans for biomedical application. Macromol Symp 2010, 296:446-452.